Bot Detector
IJPC Seal
Download FREE Sample Issue or Article
LEARN MORE
Subscribe Today
A subscription to IJPC provides on-line access to full-text, full-color, printable PDF copies of your subscribed issues, individual articles, and purchased archives.

Pharmaceutical Compounding or Pharmaceutical Manufacturing? A Regulatory Perspective

Author(s):  Timko Robert J, Crooker Philip EM

Issue:  Mar/Apr 2014 - Volume 18, Number 2
View All Articles in Issue

Page(s):  101-111

Pharmaceutical Compounding or Pharmaceutical Manufacturing? A Regulatory Perspective Page 1
Pharmaceutical Compounding or Pharmaceutical Manufacturing? A Regulatory Perspective Page 2
Pharmaceutical Compounding or Pharmaceutical Manufacturing? A Regulatory Perspective Page 3
Pharmaceutical Compounding or Pharmaceutical Manufacturing? A Regulatory Perspective Page 4
Pharmaceutical Compounding or Pharmaceutical Manufacturing? A Regulatory Perspective Page 5
Pharmaceutical Compounding or Pharmaceutical Manufacturing? A Regulatory Perspective Page 6
Pharmaceutical Compounding or Pharmaceutical Manufacturing? A Regulatory Perspective Page 7
Pharmaceutical Compounding or Pharmaceutical Manufacturing? A Regulatory Perspective Page 8
Pharmaceutical Compounding or Pharmaceutical Manufacturing? A Regulatory Perspective Page 9
Pharmaceutical Compounding or Pharmaceutical Manufacturing? A Regulatory Perspective Page 10
Pharmaceutical Compounding or Pharmaceutical Manufacturing? A Regulatory Perspective Page 11

Download in electronic PDF format for $75

Abstract:  At one time, nearly all prescriptions were compounded preparations. There is an ongoing demand for compounded prescription medications because manufacturers cannot fulfill the needs of all individual patients. Compounding pharmacies are a long standing yet less frequently discussed element in the complex matrix of prescription drug manufacturing, distribution, and patient use. The drug shortage situation for many necessary and life-saving drug products is a complicating factor that has led to the numerous quality issues that currently plague large-scale compounding pharmacies. The states are the primary regulator of pharmacies, including community drug stores, large chains, and specialty pharmacies. Pharmacies making and distributing drugs in a way that is outside the bounds of traditional pharmacy compounding are of great concern to the U.S. Food and Drug Administration. The U.S. Congress has recently passed the Drug Quality and Security Act. This legislation establishes a clear boundary between traditional compounders and compounding manufacturers. It clarifies a national, uniform set of rules for compounding manufacturers while preserving the states’ primary role in traditional pharmacy regulation. It clarifies the U.S. Food and Drug Administration’s authority over the compounding of human drugs while requiring the Agency to engage and coordinate with states to ensure the safety of compounded drugs.

Related Keywords: Robert J. Timko, RPh, PhD, Philip E.M. Crooker, compounding history, traditional compounding, U.S. Drug Quality and Security Act, drug safety, pharmacy regulation, pharmaceutical manufacturing, state boards of pharmacy, drug contamination, outsourcing facilities, good manufacturing practices, professional pharmacy compounding associations

Related Categories: HISTORY, LEGAL, QUALITY CONTROL, PATIENT EDUCATION, UNITED STATES PHARMACOPEIA CONVENTIONS, PROFESSIONAL ISSUES

Printer-Friendly Version



Related Articles from IJPC
Title/Author
(Click for Abstract / Details / Purchase)
Issue/​Page
View/Buy
Pharmaceutical Compounding or Pharmaceutical Manufacturing? A Regulatory Perspective
Timko Robert J
, Crooker Philip EM
Mar/Apr 2014
Pg. 101-111

Compounding in the Pharmacy Curriculum: Beyond the Basics
Hinkle Amanda R
, Newton Gail D
May/Jun 2004
Pg. 181-185

Standing Together Fixing the Drug Quality and Security Act
Miller David G
Mar/Apr 2015
Pg. 104-106

PreScription: Drug Quality and Security Act Implementation Subcommittee Hearing
Allen Loyd V Jr
Mar/Apr 2018
Pg. 92

Applying Quality of Design Concepts to Pharmacy Compounding
Timko Robert J
Nov/Dec 2015
Pg. 453-463

Discrepancies in the Law and the U.S. Food and Drug Administration Pharmacy Compounding Compliance Policy Guidelines
Allen Loyd V Jr
Jul/Aug 2016
Pg. 351

View Sample
Documentation: Records and Reports
Akers Michael J
Sep/Oct 2017
Pg. 373-380

The Role of Compounding in Closing Therapeutic Gaps--Abstracts from FIP 2013
Lutz Eugene
, Pauletti Giovanni, Carvalho Maria, Davidson Gigi, Ashworth Lisa, Subramaniam Vaiyapuri, Llambí Francesc
Jan/Feb 2014
Pg. 6-12

Safety Standards in Pharmaceutical Compounding, Part 3: Fire Safety
Allen W Chris
, Greeson Nicole MH, Mixon William
Nov/Dec 2020
Pg. 451-458

Pharmaceutical Compounding: The Oldest, Most Symbolic, and Still Vital Part of Pharmacy
Kochanowska-Karamyan Anna J
Sep/Oct 2016
Pg. 367-374

Nominations of Difficult to Compound Drugs to the U.S. Food and Drug Administration--Pharmacy Compounding Advisory Committee: Part 1
Allen Loyd V Jr
Sep/Oct 2015
Pg. 389-390

Incorporating Quality Assurance in Pharmaceutical Compounding-related Courses in the PharmD Curricula
Hossain Mohammad Faisal
, Levesque Dan, Frye John, Rashid Mamoon
Jul/Aug 2020
Pg. 322-326

U.S. Food and Drug Administration Requests for Input on HR 3204 Enactment: The Drug Quality and Security Act of 2013
Miller David G
Jan/Feb 2014
Pg. 35-36

PreScription: 2017 Pharmacy Compounding Issues: The U.S. Food and Drug Administration, Harzardous Drugs, and Wasted Drugs
Allen Loyd V Jr
Sep/Oct 2017
Pg. 356

U.S. Food and Drug Administration "Evaluation Criteria" for Difficult to Compound Drugs
Allen Loyd V Jr
Nov/Dec 2015
Pg. 487-488

Current Topical Treatments in Wound Healing - Part 1
Helmke Christopher D
Jul/Aug 2004
Pg. 269-274

Regulatory and Operational Issues of Founding a Compounding Pharmacy
Smith Lisa K
Nov/Dec 2002
Pg. 434-437

Quality Assurance and Quality Control: Being Prepared for U.S. Food and Drug Administration Inspections and Staying in Compliance with United States Pharmacopeia Chapter <797>: Part 1
Martin Matt
Sep/Oct 2018
Pg. 401-404

Legislative/Regulatory Update: From the International Academy of Compounding Pharmacists: Appropriations
McCrory Gary
Mar/Apr 2016
Pg. 95-96

Determining Whether a Substance is Legal to Compound with Under Section 503A of the FDCA
Cabaleiro Joe
Sep/Oct 2021
Pg. 358-362

Return to Top